Santiago Fernandez Gonzalez

Santiago Fernandez Gonzalez

Auto-generated profile, based on publicly available information

Santiago Fernandez Gonzalez

Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2012 in Nature Immunology
Verified
Journal Article
Open access
PDF file
TCthe Immunological Genome Project Consortium
the Immunological Genome Project Consortium
DMDeepali Malhotra
Deepali Malhotra
AFAnne L Fletcher
Anne L Fletcher
JAJillian Astarita
Jillian Astarita
VLVeronika Lukacs-Kornek
Veronika Lukacs-Kornek
STShannon J Turley
Shannon J Turley
The Immunological Genome Project aims to build a comprehensive database of gene-expression and gene-regulatory networks in the mouse immune system. Here Turley and colleagues analyze the transcriptomes of lymph-node stromal cells under steady-state and inflammatory conditions. Lymph node stromal cells (LNSCs) closely regulate immunity and self-tolerance, yet key aspects of their biology remain poorly elucidated. Here, comparative transcriptomic analyses of mouse LNSC subsets demonstrated the expression of important immune mediators, growth factors and previously unknown structural components. Pairwise analyses of ligands and cognate receptors across hematopoietic and stromal subsets suggested a complex web of crosstalk. Fibroblastic reticular cells (FRCs) showed enrichment for higher expression of genes relevant to cytokine signaling, relative to their expression in skin and thymic fibroblasts. LNSCs from inflamed lymph nodes upregulated expression of genes encoding chemokines and molecules involved in the acute-phase response and the antigen-processing and antigen-presentation machinery. Poorly studied podoplanin (gp38)-negative CD31− LNSCs showed similarities to FRCs but lacked expression of interleukin 7 (IL-7) and were identified as myofibroblastic pericytes that expressed integrin α7. Together our data comprehensively describe the transcriptional characteristics of LNSC subsets.

1 February 2009 in Immunity
Verified
Journal Article
Closed access
RRRamon Roozendaal
Ramon Roozendaal
TMThorsten R. Mempel
Thorsten R. Mempel
LPLisa A. Pitcher
Lisa A. Pitcher
SGSantiago F. Gonzalez
Santiago F. Gonzalez
AVAdmar Verschoor
Admar Verschoor
MCMichael C. Carroll
Michael C. Carroll

1 August 2012 in Immunity
Verified
Journal Article
Open access
SASophie E. Acton
Sophie E. Acton
JAJillian L. Astarita
Jillian L. Astarita
DMDeepali Malhotra
Deepali Malhotra
VLVeronika Lukacs-Kornek
Veronika Lukacs-Kornek
BFBettina Franz
Bettina Franz
STShannon J. Turley
Shannon J. Turley
To initiate adaptive immunity, dendritic cells (DCs) move from parenchymal tissues to lymphoid organs by migrating along stromal scaffolds that display the glycoprotein podoplanin (PDPN). PDPN is expressed by lymphatic endothelial and fibroblastic reticular cells and promotes blood-lymph separation during development by activating the C-type lectin receptor, CLEC-2, on platelets. Here, we describe a role for CLEC-2 in the morphodynamic behavior and motility of DCs. CLEC-2 deficiency in DCs impaired their entry into lymphatics and trafficking to and within lymph nodes, thereby reducing T cell priming. CLEC-2 engagement of PDPN was necessary for DCs to spread and migrate along stromal surfaces and sufficient to induce membrane protrusions. CLEC-2 activation triggered cell spreading via downregulation of RhoA activity and myosin light-chain phosphorylation and triggered F-actin-rich protrusions via Vav signaling and Rac1 activation. Thus, activation of CLEC-2 by PDPN rearranges the actin cytoskeleton in DCs to promote efficient motility along stromal surfaces.

1 June 2013 in Immunity
Verified
Journal Article
Closed access
BHBalthasar A. Heesters
Balthasar A. Heesters
PCPriyadarshini Chatterjee
Priyadarshini Chatterjee
YKYoung-A. Kim
Young-A. Kim
SGSantiago F. Gonzalez
Santiago F. Gonzalez
MKMichael P. Kuligowski
Michael P. Kuligowski
MCMichael C. Carroll
Michael C. Carroll

21 March 2010 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
SGSantiago F Gonzalez
Santiago F Gonzalez
VLVeronika Lukacs-Kornek
Veronika Lukacs-Kornek
MKMichael P Kuligowski
Michael P Kuligowski
LPLisa A Pitcher
Lisa A Pitcher
SDSøren Degn
Søren Degn
MCMichael C Carroll
Michael C Carroll

23 November 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SESilke Eisinger
Silke Eisinger
DSDhifaf Sarhan
Dhifaf Sarhan
VBVanessa F. Boura
Vanessa F. Boura
IIItziar Ibarlucea-Benitez
Itziar Ibarlucea-Benitez
STSofia Tyystjärvi
Sofia Tyystjärvi
MKMikael C. I. Karlsson
Mikael C. I. Karlsson
Significance: Here we report that targeting the pattern recognition receptor MARCO on macrophages within the tumor alters their polarization and in turn activate natural killer (NK) cells to kill the tumor. We describe the mechanism of action, including that NK cells are induced to use receptor-mediated killing of the cancer cells. Furthermore, we find that this type of treatment works in combination with T cell-targeted checkpoint therapies. We then transfer this finding to humans and find that similar subpopulations of human macrophages also block NK cells. Finally, we find that targeting these human macrophages with a new specific antibody that we generated can activate these to release NK cell killing, thus generating a venue for combinatory treatments for cancer.